Method for reducing lung infection
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11382884-B2
Publication Date
2022-07-12
Expiration Date
Abstract
A method of treating or preventing a bacterial infection in the lung of a subject by administering an inhaled antibiotic, and at least 37.5 mg/day of an inhaled chelating agent, each in one or more doses, wherein the or each dose of the chelating agent and/or antibiotic is administered over a period of no more than 8h.
Core Innovation
The disclosure relates to treating or preventing bacterial lung infections in a subject by administering, by inhalation, an inhaled antibiotic together with an inhaled chelating agent. The administration includes specific daily dose ranges for the inhaled antibiotic and the inhaled chelating agent, with one or more doses of each active administered over a period of no more than 2 h, in the absence of acidified nitrite, and with the inhaled chelating agent at a concentration of at least 50 mM.
Chelation deprives bacteria of essential metal ions such as iron and zinc. The chelating agent is described as disrupting biofilms and increasing membrane permeability, with associated antibacterial effects, and as decreasing MMP activity and hydroxyl radical production.
Inhaled delivery modalities described include nebuliser and dry powder inhaler approaches, with puffer/MDI options also described. The disclosure also includes kit and composition aspects that contain an inhaled chelating agent and/or an inhaled antibiotic and instructions specifying the inhaled daily delivery regimen, while excluding acidified nitrite.
Claims Coverage
The document provides three independent claim families, centered on the combined inhaled antibiotic and inhaled chelating agent treatment regimen with coordinated dose ranges, a maximum administration duration, exclusion of acidified nitrite, and a minimum chelating-agent concentration of at least 50 mM. The independent claim features are the defined inhaled daily dosing ranges, the coordinated dosing period of no more than 2 h, the absence of acidified nitrite, and the corresponding kit and composition claims.
Inhaled antibiotic plus inhaled chelating agent lung treatment with constrained timing and absence of acidified nitrite
A method of treating a bacterial infection in the lung of a subject by administering from 10 mg/day to 2,000 mg/day of an inhaled antibiotic and from 37.5 mg/day to 1,200 mg/day of an inhaled chelating agent, each in one or more doses administered over a period of no more than 2 h, in the absence of acidified nitrite.
Minimum chelating-agent concentration for inhaled delivery
The method further specifies that the chelating agent is administered at a concentration of at least 50 mM.
Treatment kit with instructions specifying coordinated inhaled daily doses and maximum administration duration
A kit for treating a bacterial infection in the lung of a subject containing an inhaled chelating agent and instructions for use, wherein from 37.5 mg/day to 1,200 mg/day of the inhaled chelating agent is delivered with from 10 mg/day to 2,000 mg/day of an inhaled antibiotic, with one or more doses of each of the chelating agent and/or antibiotic administered over a period of no more than 2 h.
Kit exclusion of acidified nitrite and minimum chelating-agent concentration
The kit claim requires that the inhaled chelating agent is at a concentration of at least 50 mM and that the kit does not comprise acidified nitrite.
Inhalable composition with coordinated daily dose ranges for chelating agent and antibiotic and minimum concentration
A composition comprising from 37.5 mg/day to 1,200 mg/day of an inhaled chelating agent and from 10 mg/day to 2,000 mg/day of an inhaled antibiotic for the treatment of infection, wherein the inhaled chelating agent is at a concentration of at least 50 mM.
Composition exclusion of acidified nitrite
The composition claim requires that the composition does not comprise acidified nitrite.
Across the independent claims, coverage is directed to inhaled treatment of bacterial lung infection using defined daily dose ranges of an inhaled antibiotic and an inhaled chelating agent, administered in one or more doses over a period of no more than 2 h, with the chelating agent at a concentration of at least 50 mM and with acidified nitrite excluded. Additional independent coverage is provided for a corresponding kit with instructions and for an inhalable composition combining the specified inhaled antibiotic and inhaled chelating agent dose ranges.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?